174 related articles for article (PubMed ID: 10590671)
1. [Increased serum soluble Fas ligand in hyperthyroid Graves' disease].
Takeda K; Ohara E; Kaneda T; Hashimoto K; Sasaki M
Rinsho Byori; 1999 Oct; 47(10):961-5. PubMed ID: 10590671
[TBL] [Abstract][Full Text] [Related]
2. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism.
Wang CY; Zhong WB; Chang TC; Tsai YF
Metabolism; 2002 Jun; 51(6):769-73. PubMed ID: 12037733
[TBL] [Abstract][Full Text] [Related]
3. Circulating nuclear matrix protein in Graves' disease.
Hara H; Morita Y; Sato R; Ban Y
Endocr J; 2002 Jun; 49(3):343-7. PubMed ID: 12201219
[TBL] [Abstract][Full Text] [Related]
4. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers.
Myśliwiec J; Okota M; Nikołajuk A; Górska M
Adv Med Sci; 2006; 51():119-22. PubMed ID: 17357290
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of soluble Fas in patients with autoimmune thyroid diseases.
Shimaoka Y; Hidaka Y; Okumura M; Takeoka K; Tada H; Amino N
Thyroid; 1998 Jan; 8(1):43-7. PubMed ID: 9492152
[TBL] [Abstract][Full Text] [Related]
6. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response.
Mysliwiec J; Oklota M; Nikolajuk A; Waligorski D; Gorska M
Immunol Invest; 2007; 36(3):247-57. PubMed ID: 17558708
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
9. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
10. Fas/FasL mediated apoptosis of thyrocytes in Graves' disease.
Sera N; Kawakami A; Nakashima T; Nakamura H; Imaizumi M; Koji T; Abe Y; Usa T; Tominaga T; Ejima E; Ashizawa K; Yokoyama N; Ishikawa N; Ito K; Eguchi K
Clin Exp Immunol; 2001 May; 124(2):197-207. PubMed ID: 11422195
[TBL] [Abstract][Full Text] [Related]
11. Increased serum soluble Fas in patients with Graves' disease.
Hiromatsu Y; Bednarczuk T; Soyejima E; Miyake I; Yang D; Fukazawa H; Nonaka K
Thyroid; 1999 Apr; 9(4):341-5. PubMed ID: 10319938
[TBL] [Abstract][Full Text] [Related]
12. [Cytofluorometric analysis of chosen markers of apoptosis CD95/CD95L (Fas/FasL) in thyroid tissues from young patients with Graves' disease and Hashimoto's thyroiditis].
Bossowski A; Stasiak-Barmuta A; Czarnocka B; Urban M; Łyczkowska A; Niedziela M; Bardadin K; Czerwińska J; Dadan J; Baltaziak M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(2):83-90. PubMed ID: 16813711
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of Fas, FasL and Caspase-8 expression in thyroid gland in young patients with immune and non-immune thyroid diseases].
Bossowski A; Czarnocka B; Stasiak-Barmuta A; Bardadin K; Urban M; Dadan J
Endokrynol Pol; 2007; 58(4):303-13. PubMed ID: 18058722
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
15. Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis.
Bossowski A; Czarnocka B; Bardadin K; Stasiak-Barmuta A; Urban M; Dadan J; Ratomski K; Bossowska A
Autoimmunity; 2008 Mar; 41(2):163-73. PubMed ID: 18324486
[TBL] [Abstract][Full Text] [Related]
16. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
[TBL] [Abstract][Full Text] [Related]
17. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome.
Doughty L; Clark RS; Kaplan SS; Sasser H; Carcillo J
Pediatr Res; 2002 Dec; 52(6):922-7. PubMed ID: 12438671
[TBL] [Abstract][Full Text] [Related]
18. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
19. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto's thyroiditis and Graves' disease.
Salmaso C; Bagnasco M; Pesce G; Montagna P; Brizzolara R; Altrinetti V; Richiusa P; Galluzzo A; Giordano C
Ann N Y Acad Sci; 2002 Jun; 966():496-501. PubMed ID: 12114310
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease.
Enjoji M; Yamaguchi K; Nakashima M; Ohta S; Kotoh K; Fukushima M; Kuniyoshi M; Tanaka M; Nakamuta M; Watanabe T; Nawata H
Liver Int; 2004 Aug; 24(4):330-4. PubMed ID: 15287856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
